Clinical Trial Update: Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating eftilagimod alfa in combination with pembrolizumab and chemotherapy versus placebo with pembrolizumab and chemotherapy in metastatic no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (platinum-based regimen) (platinum-based chemotherapy)
• Pembrolizumab (pembrolizumab)
• eftilagimod alfa (eftilagimod alfa)

Snippet

Sponsor: Immutep S.A.S. | Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: ACTIVE_NOT_RECRUITING